Polycythemia Vera (PV)
''Polycythemia vera is an uncommon myeloproliferative neoplasm in which the bone marrow makes too many red blood cells.[1] It may also result in the overproduction of white blood cells and platelets.
Most of the health concerns associated with polycythemia vera are caused by the blood being thicker as a result of the increased red blood cells. It is more common in the elderly and may be symptomatic or asymptomatic. Common signs and symptoms include itching (pruritus), and severe burning pain in the hands or feet that is usually accompanied by a reddish or bluish coloration of the skin. Patients with polycythemia vera are more likely to have gouty arthritis. Treatment consists primarily of phlebotomy.
.......
A mutation in the JAK2 kinase (V617F) is strongly associated with polycythemia vera.[14][15] JAK2 is a member of the Janus kinase family and makes the erythroid precursors hypersensitive to erythropoietin (EPO). This mutation may be helpful in making a diagnosis or as a target for future therapy.
Following history and examination, the British Committee for Standards in Haematology (BCSH) recommend the following tests are performed:If the JAK2 mutation is negative and there is no obvious secondary causes the BCSH suggest the following tests:
- full blood count/film (raised haematocrit; neutrophils, basophils, platelets raised in half of patients)
- JAK2 mutation
- serum ferritin
renal and liver function tests
- red cell mass
arterial oxygen saturation
abdominal ultrasound
serum erythropoietin level
bone marrow aspirate and trephine
cytogenetic analysis
erythroid burst-forming unit (BFU-E) culture
Extract of wikipedia
VIDEOS
Understanding Key Blood Counts in Polycythemia Vera
February 25, 2019, Voices of MPN
Polycythemia Vera for Patients ** must be seen **
October 4, 2018, UT Health San Antonio MD Anderson Cancer Center
Polycythemia Vera Diagnosis
July 6, 2017, OncLiveTV
How I Treat Polycythemia Vera - Alessandro Vannucchi, MD
August 8, 2016, American Society of Hematology
Turning a PV Diagnosis Into a Positive: One Woman’s Journey
October 8, 2015, Patient Power
What is polycythemia vera? | Hematologic System Diseases ** must be seen **
May 11, 2015, khanacademymedicine
Ask the Expert: Polycythemia Vera
April 27, 2015, OMNIConnect
Polycythemia Vera Update 2015 - Mayo Clinic
December 16, 2014, Mayo Clinic
Recent advances in the diagnosis, prognosis and survival predictions of patients with PV
October 2014, ImedexCME
Living with Polycythemia Vera
February 26, 2014, National Organization for Rare Disorders (NORD)
Polycythemia Vera Update 2014 - Mayo Clinic
December 17, 2013, Mayo Clinic
Polycythemia Vera 2012 Updates - Mayo Clinic
January 9, 2012, Mayo Clinic
Polycythemia Vera (PV) - Mayo Clinic
March 31, 2010, Mayo Clinic
Polycythemia Vera
October 1, 2009, unys25
Understanding Key Blood Counts in Polycythemia Vera
February 25, 2019, Voices of MPN
Polycythemia Vera for Patients ** must be seen **
October 4, 2018, UT Health San Antonio MD Anderson Cancer Center
Polycythemia Vera Diagnosis
July 6, 2017, OncLiveTV
How I Treat Polycythemia Vera - Alessandro Vannucchi, MD
August 8, 2016, American Society of Hematology
Turning a PV Diagnosis Into a Positive: One Woman’s Journey
October 8, 2015, Patient Power
What is polycythemia vera? | Hematologic System Diseases ** must be seen **
May 11, 2015, khanacademymedicine
Ask the Expert: Polycythemia Vera
April 27, 2015, OMNIConnect
Polycythemia Vera Update 2015 - Mayo Clinic
December 16, 2014, Mayo Clinic
Recent advances in the diagnosis, prognosis and survival predictions of patients with PV
October 2014, ImedexCME
Living with Polycythemia Vera
February 26, 2014, National Organization for Rare Disorders (NORD)
Polycythemia Vera Update 2014 - Mayo Clinic
December 17, 2013, Mayo Clinic
Polycythemia Vera 2012 Updates - Mayo Clinic
January 9, 2012, Mayo Clinic
Polycythemia Vera (PV) - Mayo Clinic
March 31, 2010, Mayo Clinic
Polycythemia Vera
October 1, 2009, unys25
ARTICLES
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
October 5, 2015, Blood Cancer Journal
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: A case report
April 2015, Journal of Medical Case Reports
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
January 29, 2015, The New England Journal of Medicine
Inherited predisposition to myeloproliferative neoplasms
May 14, 2013, Therapeutic advances in Hematology
Durable Response with the JAK1/JAK2 Inhibitor, IINCB18424, in Patients with Polycytemia Vera (PV), and Essential Thrombocytemia (ET) Refractory ro Intolerant to Hydroxyurea
December 6, 2010, ASH2010 Meeting
JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders
February 21, 2008, Leukemia
Transformation of polycythemia vera to chronic myelogenous leukemia
November 13, 2007, PubMed
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
October 5, 2015, Blood Cancer Journal
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: A case report
April 2015, Journal of Medical Case Reports
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
January 29, 2015, The New England Journal of Medicine
Inherited predisposition to myeloproliferative neoplasms
May 14, 2013, Therapeutic advances in Hematology
Durable Response with the JAK1/JAK2 Inhibitor, IINCB18424, in Patients with Polycytemia Vera (PV), and Essential Thrombocytemia (ET) Refractory ro Intolerant to Hydroxyurea
December 6, 2010, ASH2010 Meeting
JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders
February 21, 2008, Leukemia
Transformation of polycythemia vera to chronic myelogenous leukemia
November 13, 2007, PubMed